Shen, De-Liang <br/><br/>
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.  [electronic resource] 

 -  Journal of cardiovascular pharmacology  Mar 2016 
 - 232-6 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4023 
<br/><br/><label>Standard No.: </label>10.1097/FJC.0000000000000337  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenosine--adverse effects<br/>Aged<br/>Aged, 80 and over<br/>Asian People--genetics<br/>Biotransformation<br/>Chi-Square Distribution<br/>China<br/>Clopidogrel<br/>Coronary Artery Disease--ethnology<br/>Cytochrome P-450 CYP2C19--genetics<br/>Drug Monitoring--methods<br/>Female<br/>Genotype<br/>Hemorrhage--chemically induced<br/>Humans<br/>Logistic Models<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Odds Ratio<br/>Percutaneous Coronary Intervention--adverse effects<br/>Pharmacogenomic Testing<br/>Phenotype<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Platelet Function Tests<br/>Polymorphism, Genetic<br/>Risk Factors<br/>Ticagrelor<br/>Ticlopidine--adverse effects<br/>Treatment Outcome